In a recent study conducted on 65 patients with different stages of CRC, FOXP3 expression was systematically evaluated in both tumor-infiltrating lymphocytes and neoplastic cells, and was correlated to tumor progression and clinical-pathological features (56). Here, FOXP3 is linked to neoplasm.